Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;8(6):716-724.
doi: 10.21037/cdt.2018.10.16.

Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part II: infective endocarditis, pulmonary hypertension, pulmonary arterial hypertension and aortopathy

Rhoia Neidenbach  1 , Koichiro Niwa  2 , Oeztekin Oto  3 , Erwin Oechslin  4 , Jamil Aboulhosn  5 , David Celermajer  6 , Joerg Schelling  7 , Lars Pieper  8 , Linda Sanftenberg  7 , Renate Oberhoffer  1   9 , Fokko de Haan  10 , Michael Weyand  11 , Stephan Achenbach  12 , Christian Schlensak  13 , Dirk Lossnitzer  14 , Nicole Nagdyman  1 , Yskert von Kodolitsch  15 , Hans-Carlo Kallfelz  16 , David Pittrow  17 , Ulrike M M Bauer  18 , Peter Ewert  1 , Thomas Meinertz  15 , Harald Kaemmerer  1
Affiliations
Review

Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part II: infective endocarditis, pulmonary hypertension, pulmonary arterial hypertension and aortopathy

Rhoia Neidenbach et al. Cardiovasc Diagn Ther. 2018 Dec.

Abstract

Despite relevant residua and sequels, follow-up care of adults with congenital heart disease (ACHD) is too often not performed by/in specialized and/or certified physicians or centers although major problems in the long-term course may develop. The most relevant encompass heart failure, cardiac arrhythmias, heart valve disorders, pulmonary vascular disease, infective endocarditis (IE), aortopathy and non-cardiac comorbidities. The present publication emphasizes current data on IE, pulmonary and pulmonary arterial hypertension and aortopathy in ACHD and underlines the deep need of an experienced follow-up care by specialized and/or certified physicians or centers, as treatment regimens from acquired heart disease can not be necessarily transmitted to CHD. Moreover, the need of primary and secondary medical prevention becomes increasingly important in order to reduce the burden of disease as well as the socioeconomic burden and costs in this particular patient group.

Keywords: Congenital heart defect (CHD); aortopathy; endocarditis; heart failure; prevention; primary health care; pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: R Neidenbach received research grants (“Unrestricted educational grant”) from Actelion Pharmaceuticals Deutschland GmbH and from the German Heart Foundation (“Deutsche Herzstiftung e.V.”) and the patient organization “Herzkind e. V.”; H Kaemmerer received fees and/or travel expenses for consulting activities and/or lectures from the following companies within the last 3 years: Actelion, Pfizer, Bayer-Healthcare, Bristol-Myers Squibb; D Pittrow has received speaker fees or honoraria for consultations from Actelion, Bayer, Genzyme, Boehringer Ingelheim, Novartis, MSD. and Dr. Erwin Oechslin currently holds the “Bitove Family Professorship for Adult Congenital Heart Disease”. Other author have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Use of antibiotic prophylaxis for the prevention of IE due to dental procedures, according to the ACC/AHA and ESC guidelines (20,21). IE, infective endocarditis; ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology.
Figure 2
Figure 2
Differential diagnostic aspects in pulmonary hypertension due to congenital heart disease (32). PAH, pulmonary arterial hypertension.
Figure 3
Figure 3
Suspected diagnosis of PAH associated with congenital heart disease/Eisenmenger syndrome. Modified from (31). PAH, pulmonary arterial hypertension.
See this image and copyright information in PMC

References

    1. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132:1435-86. 10.1161/CIR.0000000000000296 - DOI - PubMed
    1. Correa de Sa DD, Tleyjeh IM, Anavekar NS, et al. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 2010;85:422-6. 10.4065/mcp.2009.0585 - DOI - PMC - PubMed
    1. Duval X, Delahaye F, Alla F, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol 2012;59:1968-76. 10.1016/j.jacc.2012.02.029 - DOI - PubMed
    1. Federspiel JJ, Stearns SC, Peppercorn AF, et al. Increasing US rates of endocarditis with Staphylococcus aureus: 1999-2008. Arch Intern Med 2012;172:363-5. 10.1001/archinternmed.2011.1027 - DOI - PMC - PubMed
    1. Abdulhak AA, Baddour LM, Erwin PJ, et al. Global and regional burden of infective endocarditis, 1990–2010: a systematic review of the literature. Global Heart 2014;9:131-43. 10.1016/j.gheart.2014.01.002 - DOI - PubMed